Liver fibrosis therapy based on biomimetic nanoparticles which deplete activated hepatic stellate cells.

[1]  Xiangrui Liu,et al.  Macrophage-evading and tumor-specific apoptosis inducing nanoparticles for targeted cancer therapy , 2022, Acta pharmaceutica Sinica. B.

[2]  H. Santos,et al.  Autologous Skin Fibroblast‐Based PLGA Nanoparticles for Treating Multiorgan Fibrosis , 2022, Advanced science.

[3]  G. Hong,et al.  Red Blood Cell Membrane-Camouflaged PLGA Nanoparticles Loaded With Basic Fibroblast Growth Factor for Attenuating Sepsis-Induced Cardiac Injury , 2022, Frontiers in Pharmacology.

[4]  M. L. Dias,et al.  Liver cirrhosis: An overview of experimental models in rodents. , 2022, Life sciences.

[5]  Yifan Li,et al.  Combination therapy based on targeted nano drug co-delivery systems for liver fibrosis treatment: a review , 2022, Journal of drug targeting.

[6]  Jiyao Li,et al.  Fibroblast membrane-camouflaged nanoparticles for inflammation treatment in the early stage , 2021, International journal of oral science.

[7]  Lifang Yin,et al.  Resolving hepatic fibrosis via suppressing oxidative stress and an inflammatory response using a novel hyaluronic acid modified nanocomplex. , 2021, Biomaterials science.

[8]  Tinghong Ye,et al.  Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy , 2021, Frontiers in Cell and Developmental Biology.

[9]  W. Shou,et al.  Heterogeneity of Hepatic Stellate Cells in Fibrogenesis of the Liver: Insights from Single-Cell Transcriptomic Analysis in Liver Injury , 2021, Cells.

[10]  Zhiqiang Yan,et al.  Long Circulation of PEG-TRAIL Improves Anti-Hepatic Fibrosis Effect of TRAIL Via Targeting Activated Hepatic Stellate Cells , 2021, Frontiers in Materials.

[11]  Ronnie H. Fang,et al.  Genetically engineered cell membrane–coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs , 2021, Science Advances.

[12]  R. Bourgon,et al.  Cross-tissue organization of the fibroblast lineage , 2021, Nature.

[13]  B. Charloteaux,et al.  Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity , 2021, JHEP reports : innovation in hepatology.

[14]  S. Ahadian,et al.  Bioengineered Multicellular Liver Microtissues for Modeling Advanced Hepatic Fibrosis Driven Through Non-Alcoholic Fatty Liver Disease. , 2021, Small.

[15]  Leaf Huang,et al.  Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis , 2021, Nature Nanotechnology.

[16]  C. Cho,et al.  Progress in drug delivery system for fibrosis therapy , 2020, Asian journal of pharmaceutical sciences.

[17]  F. Tacke,et al.  Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities , 2020, Cellular & molecular immunology.

[18]  Shumei Zhai,et al.  Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis , 2020, Nanomaterials.

[19]  T. Enver,et al.  Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine , 2020, Nature Communications.

[20]  Lungen Lu,et al.  Antihepatic Fibrosis Drugs in Clinical Trials , 2020, Journal of clinical and translational hepatology.

[21]  Chunxi Wang,et al.  Cell Membrane-Camouflaged Nanocarriers for Cancer Diagnostic and Therapeutic , 2020, Frontiers in Pharmacology.

[22]  Gang Liu,et al.  TRAIL-expressing cell membrane nanovesicles as an anti-inflammatory platform for rheumatoid arthritis therapy. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[23]  D. He,et al.  Cell Membrane-camouflaged Nanoparticles as Drug Carriers for Cancer Therapy. , 2020, Acta biomaterialia.

[24]  B. Hinz,et al.  Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases , 2019, Nature Reviews Rheumatology.

[25]  L. Deng,et al.  Recent advance of erythrocyte-mimicking nanovehicles: from bench to bedside. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[26]  J. Esplugues,et al.  Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells , 2019, Gut.

[27]  M. Yokoyama,et al.  Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review , 2019, Science and technology of advanced materials.

[28]  Zhirong Zhang,et al.  Golgi Apparatus-Targeted Chondroitin-Modified Nanomicelles Suppress Hepatic Stellate Cell Activation for the Management of Liver Fibrosis. , 2019, ACS nano.

[29]  Akshay Jain,et al.  Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[30]  Ami A. Shah,et al.  Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma , 2019, Nature Communications.

[31]  Hong Tang,et al.  Insight into the role of TRAIL in liver diseases. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[32]  Zhuxian Zhou,et al.  New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast‐enriched tumor microenvironment , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Xu Zhen,et al.  Cell Membrane Coated Semiconducting Polymer Nanoparticles for Enhanced Multimodal Cancer Phototheranostics. , 2018, ACS nano.

[34]  Hao Cheng,et al.  PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy , 2018, Advanced materials.

[35]  D. Schuppan,et al.  Determinants of fibrosis progression and regression in NASH. , 2018, Journal of hepatology.

[36]  H. Walczak,et al.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy , 2017, Nature Reviews Cancer.

[37]  K. Faber,et al.  Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells , 2017, Journal of drug targeting.

[38]  Pengcheng Zhang,et al.  Cancer‐Cell‐Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors , 2016, Advanced materials.

[39]  G. Gores,et al.  Paving the TRAIL to anti‐fibrotic therapy , 2016, Hepatology.

[40]  M. Pomper,et al.  Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells , 2016, Hepatology.

[41]  Xiao-ming Meng,et al.  TGF-β: the master regulator of fibrosis , 2016, Nature Reviews Nephrology.

[42]  S. Hahn,et al.  Hyaluronic acid-tumor necrosis factor-related apoptosis-inducing ligand conjugate for targeted treatment of liver fibrosis. , 2015, Acta biomaterialia.

[43]  H. Wong,et al.  A new nanostructured carrier design including oil to enhance the pharmaceutical properties of retinoid therapy and its therapeutic effects on chemo-resistant ovarian cancer. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[44]  Frank Tacke,et al.  Macrophage heterogeneity in liver injury and fibrosis. , 2014, Journal of hepatology.

[45]  V. Thannickal,et al.  Reversal of Persistent Fibrosis in Aging by Targeting Nox4-Nrf2 Redox Imbalance , 2014, Science Translational Medicine.

[46]  F. Zhang,et al.  Discussion about several potential drawbacks of PEGylated therapeutic proteins. , 2014, Biological & pharmaceutical bulletin.

[47]  H. Wong,et al.  A novel hybrid delivery system: polymer-oil nanostructured carrier for controlled delivery of highly lipophilic drug all-trans-retinoic acid (ATRA). , 2012, International journal of pharmaceutics.

[48]  Y. Yoshioka,et al.  Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. , 2012, Biological & pharmaceutical bulletin.

[49]  Christopher K. Glass,et al.  Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis , 2012, Proceedings of the National Academy of Sciences.

[50]  Ronnie H. Fang,et al.  Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform , 2011, Proceedings of the National Academy of Sciences.

[51]  R. Herbst,et al.  Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  S. I. Park,et al.  Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells. , 2009, Cellular signalling.

[53]  E. Mezey,et al.  Effects of retinoic acid on the development of liver fibrosis produced by carbon tetrachloride in mice. , 2007, Biochimica et biophysica acta.

[54]  D. Meijer,et al.  The Antiproliferative Drug Doxorubicin Inhibits Liver Fibrosis in Bile Duct-Ligated Rats and Can Be Selectively Delivered to Hepatic Stellate Cells in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.

[55]  G. Gores,et al.  Activated stellate cells express the TRAIL receptor‐2/death receptor‐5 and undergo TRAIL‐mediated apoptosis , 2003, Hepatology.

[56]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[57]  G. Shopp,et al.  Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.